REDOXTHERAPIES
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. Redox has compiled key assets in this space, including an exclusive license to vipadenant, a potent and selective A2a adenosine receptor antagonist, and intellectual property covering the combination of adenosine antagonists with immuno-modulatory agents.
REDOXTHERAPIES
Industry:
Health Care Pharmaceutical
Founded:
2006-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Status:
Active
Contact:
(617)742-3055
Similar Organizations
Superlative BioSciences
We provide superlative biosciences services.
Unique Pharmaceuticals
Unique Pharmaceuticals provides sterile and non-sterile outsourcing services.